Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

References

• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet369(9580), 2196–2210 (2007).
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine24(22), 4692–4700 (2006).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev.31, 101–107 (2007).
   PubMed Web of Science ®Google Scholar
• Trotter CL, McVernon J, Ramsay ME et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine26(35), 4434–4445 (2008).
   PubMed Web of Science ®Google Scholar
• Fine PEM. Herd immunity: history, theory, practise. Epidemiol. Rev.15(2), 265–302 (1993).
   PubMed Web of Science ®Google Scholar
• Fine PE. Community Immunity. In: Vaccines (4th Edition). Plotkin SA, Orenstein WO (Eds). Saunders, PA, USA, 1443–1462 (2004).
   Google Scholar
• Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, UK (1991).
   Google Scholar
• Greenwood B. Meningococcal meningitis in Africa. Trans. Royal Soc. Trop. Med. & Hygiene93, 341–353 (1999).
   PubMed Web of Science ®Google Scholar
• WHO. Control of epidemic meningococcal disease. WHO Practical Guidelines (2nd Edition). WHO, Geneva, Switzerland (1998).
   Google Scholar
• Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux JP. Epidemiology of bacterial meningitis in Niamey, Niger, 1981–1996. Bull. World Health Organ.77(6), 499–508 (1999).
   PubMed Web of Science ®Google Scholar
• Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975–1991. NIPH Ann.14(2), 57–65 (1991).
   PubMedGoogle Scholar
• Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo Cruz94(4), 433–440 (1999).
   PubMed Web of Science ®Google Scholar
• Baker M, Martin D, Kieft C. The evolving meningococcal disease epidemic in New Zealand. NZ Public Health Rep.6(No. 8), 57–61 (1999).
   Google Scholar
• O’Hallahan J, Lennon D, Oster P et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine23(17–18), 2197–2201 (2005).
   PubMed Web of Science ®Google Scholar
• Greenwood B. The changing face of meningococcal disease in West Africa. Epidemiol. Infect.135(5), 703–705 (2007).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Chandra M, Cano R et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol. Rev.31, 27–36 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BE, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J. Infect. Dis.180, 1894–1901 (1999).
   PubMed Web of Science ®Google Scholar
• Leimkugel J, Hodgson A, Forgor AA et al. Clonal waves of Neisseria colonisation and disease in the African Meningitis belt: eight-year longitudinal study in northern Ghana. PLoS Med.4(3), e101(2007).
   PubMed Web of Science ®Google Scholar
• EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2003/04. Health Protection Agency, London, UK (2006).
   Google Scholar
• Booy R, Habibi P, Nadel S et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch. Dis. Child.85, 386–390 (2001).
   PubMed Web of Science ®Google Scholar
• Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch. Dis. Child.85, 382–385 (2001).
   PubMed Web of Science ®Google Scholar
• Wenzel P. Non-usefulness of carriage rates. Lancet2, 205(1973).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect.134(3), 556–566 (2006).
   PubMed Web of Science ®Google Scholar
• Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol. Rev.31(1), 52–63 (2007).
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol.53(Pt 9), 821–832 (2004).
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Bowen L, Hickman M. Neisseria meningitidis carriage by age: a systematic review. Presented at: 16th International Pathogenic Neisseria Conference. Rotterdam, the Netherlands, 7–12 September 2008.
   Google Scholar
• Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt: a review. Lancet Infect. Dis.7(12), 797–803 (2007).
   PubMed Web of Science ®Google Scholar
• Ravenscroft N, Feavers IM. Conjugate vaccines. In: Handbook of Meningococcal Disease. Infection, Biology, Vaccination, Clinical Management (1st Edition). Frosch M, Maiden MCJ (Eds). Wiley–VCH Verlag GmbH & Co., Weinheim, Germany, 343–369 (2006).
   Google Scholar
• Robbins JB, Towne DW, Gotslich EC, Schneerson R. ‘Love’s labours lost’: failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet350, 880–883 (1997).
   PubMed Web of Science ®Google Scholar
• Goldblatt D. Conjugate vaccines. Clin. Exp. Immunol.119(1), 1–3 (2000).
   PubMed Web of Science ®Google Scholar
• Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect. Dis.8(7), 435–443 (2008).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury DM, Ramsay ME. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20, S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• CDC. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR Morb. Mortal. Wkly Rep.56(31), 794–795 (2007).
   PubMedGoogle Scholar
• LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine25(S), A97–A100 (2007).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2(8346), 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccin.3(6), 290–294 (2007).
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340(8827), 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen G, van Dijken H, Hamstra H-J, Ummels R, van Alphen L, van der Lay PP. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. Presented at: 14th International Pathogenic Neisseria Conference. Milwaukee, WI, USA, 5–10 September 2004.
   Google Scholar
• Giuliani MM, du-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J.20(1), 63–75 (2001).
   PubMed Web of Science ®Google Scholar
• Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop. Med. Int. Health12(12), 1409–1421 (2007).
   PubMed Web of Science ®Google Scholar
• Bjune G. ‘Herd immunity’ and the meningococcal vaccine trial in Norway. Lancet340(8814), 315(1992).
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15, P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine13(9), 821–829 (1995).
   PubMed Web of Science ®Google Scholar
• Perkins BA, Jonsdottir K, Briem H et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177(3), 683–691 (1998).
   PubMed Web of Science ®Google Scholar
• Stephens DS. Vaccines for the unvaccinated: protecting the herd. J. Infect. Dis.197, 643–645 (2008).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Surrogates of protection. In: Handbook of Meningococcal Disease: Infection Biology, Vaccination, Clinical Management. Frosch M, Maiden MC (Eds). Wiley-VCH, Weinheim, Germany, 323–341 (2006).
   Google Scholar
• Zhang Q, Finn A. Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J. Clin. Pathol.57(10), 1015–1021 (2004).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Public Health5(3), 220–225 (2002).
   PubMedGoogle Scholar
• Maiden MCJ, Stuart JM, on behalf of the UK Meningococcal Carriage Group. Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination. Lancet359, 1829–1830 (2002).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197, 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• Farrington CP. Estimation of vaccine effectiveness using the screening method. Int. J. Epidemiol.22(5), 742–746 (1993).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364(9431), 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J326(7385), 365–366 (2003).
   PubMed Web of Science ®Google Scholar
• Dolan-Livengood JM, Miller YK, Martin LE, Urwin R, Stephens DS. Genetic basis for nongroupable Neisseria meningitidis. J. Infect. Dis.187(10), 1616–1628 (2003).
   PubMed Web of Science ®Google Scholar
• Weber MV, Claus H, Maiden MC, Frosch M, Vogel U. Genetic mechanisms for loss of encapsulation in polysialyltransferase-gene-positive meningococci isolated from healthy carriers. Int. J. Med. Microbiol.296(7), 475–484 (2006).
   PubMed Web of Science ®Google Scholar
• Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N. Engl. J. Med.342(3), 219–220 (2000).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunization with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect. Dis.6(10), 616–617 (2006).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol.162(1), 89–100 (2005).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd immunity. Med. Decis. Making23(1), 76–82 (2003).
   PubMed Web of Science ®Google Scholar
• De WP. Meningococcal C vaccines: the Canadian experience. Pediatr. Infect. Dis. J.23(12 Suppl.), S280–S284 (2004).
   Google Scholar
• De Wals P, Trottier P, Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine24(17), 3500–3504 (2006).
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23(32), 4097–4100 (2005).
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA292(20), 2491–2494 (2004).
   PubMed Web of Science ®Google Scholar
• Welte R, van den DG, Bos JM et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programs in the Netherlands and its impact on decision-making. Vaccine23(4), 470–479 (2004).
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van DA. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr. Infect. Dis. J.25(1), 79–80 (2006).
   PubMed Web of Science ®Google Scholar
• Kinlin LM, Jamieson F, Brown EM et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006. Vaccine27(11), 1735–1740 (2009).
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr. Infect. Dis. J.24(2), 128–131 (2005).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Borrow R, Findlow J et al. Seroprevalence of antibodies against serogroup C meningococci in England in the post-vaccination era. Clin. Vaccine Immunol.15(11), 1694–1698 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas HL, Andrews N, Trotter C, Ramsay M, Miller E. Meningococcal C booster not recommended by evidence. Br. Med. J337, a1139(2008).
   Google Scholar
• Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet354(9179), 615–616 (1999).
   PubMed Web of Science ®Google Scholar
• Perez-Trallero E, Vicente D, Montes M, Cisterna R. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet360, 953(2002).
   PubMed Web of Science ®Google Scholar
• Castilla J, Vazquez JA, Salcedo C et al. B:2a:p1.5 meningococcal strains likely arisen from capsular switching event still spreading in Spain. J. Clin. Microbiol.47(2), 463–465 (2009).
   PubMed Web of Science ®Google Scholar
• Law DK, Stoltz J, Henderson AM, Tsang RS. Antigenic and genetic characterization of serogroup C meningococci isolated from invasive meningococcal disease cases in Canada from 1999 to 2003. Can. J. Microbiol.51(7), 523–530 (2005).
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis.196(9), 1346–1354 (2007).
   PubMed Web of Science ®Google Scholar
• McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. Br. Med. J329(7467), 655–658 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Vaccination coverage among adolescents aged 13–17 years – United States, 2007. MMWR Morb. Mortal. Wkly Rep.57(40), 1100–1103 (2008).
   PubMedGoogle Scholar
• Clark TA, Stern EJ, Pondo T et al. The effect of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. Presented at: 16th International PathogenicNeisseria Conference.Rotterdam, the Netherlands, 7–12 September 2008.
   Google Scholar
• Chanteau S, Sidikou F, Djibo S, Moussa A, Mindadou H, Boisier P. Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt, indisputable benefits of multiplex PCR assay in Niger. Trans. R. Soc. Trop. Med. Hyg.100(7), 677–680 (2006).
   PubMed Web of Science ®Google Scholar
• Claus H, Maiden MC, Maag R, Frosch M, Vogel U. Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology148(Pt 6), 1813–1819 (2002).
   PubMed Web of Science ®Google Scholar